Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Frequently asked questions
What sector does Camurus AB (CAMX) operate in?
Camurus AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Camurus AB (CAMX) current stock price?
As of the latest data, Camurus AB stock price is SEK 667.50, with a previous close of SEK 666.00. Camurus AB gained SEK 1.50 in the last trading session, representing a 0.23% increase.
What is Camurus AB (CAMX) current market capitalization?
Camurus AB market cap is approximately 39.72 billion.
What is Camurus AB (CAMX) Earnings Per Share (EPS)?
The trailing EPS is SEK 11.31, and the forward EPS is SEK 21.43.
What is Camurus AB (CAMX) Price-to-Earnings (P/E) ratio?
Camurus AB current P/E ratio is 59.02, with a forward P/E of 31.15.
What is Camurus AB (CAMX) EBITDA?
Camurus AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 318.23 million.
Does Camurus AB (CAMX) pay dividends?
No. Camurus AB does not pay a dividend.
How did Camurus AB (CAMX) perform in its most recent earnings report?
In the last report (June 30, 2026), Camurus AB posted an EPS surprise of 24.62% and a revenue surprise of 11.15%.
When is Camurus AB (CAMX) next earnings report?
Camurus AB is expected to release its next earnings report on September 30, 2026.
What is Camurus AB (CAMX) beta (volatility) score?
Camurus AB has a beta of 0.510, indicating lower volatility than the overall market.
